Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocriplasmin Research to Better Inform Treatment (ORBIT)

Trial Profile

Ocriplasmin Research to Better Inform Treatment (ORBIT)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocriplasmin (Primary)
  • Indications Retinal disorders
  • Focus Therapeutic Use
  • Acronyms ORBIT
  • Sponsors Oxurion; ThromboGenics
  • Most Recent Events

    • 11 May 2017 According to a ThromboGenics media release, data from this trial were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2017 annual meeting
    • 20 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 29 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top